troglitazone has been researched along with Sarcoma in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pruimboom-Brees, IM | 1 |
| Francone, O | 1 |
| Pettersen, JC | 1 |
| Kerlin, RL | 1 |
| Will, Y | 1 |
| Amacher, DE | 1 |
| Boucher, GG | 1 |
| Morton, D | 1 |
1 other study available for troglitazone and Sarcoma
| Article | Year |
|---|---|
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; | 2012 |